^
    Back
    Association details:
    Biomarker:IL6R L
    Cancer:Renal Cell Carcinoma
    Drug:sunitinib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ScienceDirect
    Title:

    Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma

    Excerpt:
    Forty-six patients with metastatic or non-resectable ccRCC treated with sunitinib...patients with a decrease in concentration of pIL6R between baseline and week 12 showed significantly improved PFS (log rank, p = 0.04)...
    DOI:
    10.1016/j.ctarc.2019.100127